TrueBinding is a clinical-stage biotechnology company focused on developing novel therapeutics for Alzheimer's disease and other neurodegenerative disorders. The company is headquartered in San Francisco, California, with a mission to advance breakthrough treatments that address the underlying pathology of Alzheimer's disease and related conditions.
- Founded: 2017
- Headquarters: San Francisco, California, USA
- Focus: Alzheimer's disease, Neurodegeneration
- CEO: Dr. Jack E. Browe
- 2023: Series B funding round
- 2021: Series A funding round
- Total funding: Multiple rounds totaling significant investment
TB-001 is TrueBinding's lead clinical candidate for Alzheimer's disease.
| Property |
Description |
| Type |
Monoclonal antibody |
| Target |
Amyloid-beta plaques and oligomers |
| Indication |
Alzheimer's Disease |
| Mechanism |
Binding to amyloid-beta to promote clearance |
| Phase |
Phase 1 (Clinical) |
| Status |
Active clinical trial |
Development Highlights:
- Novel antibody with high affinity for aggregated amyloid-beta
- Designed to target both plaques and soluble oligomers
- Potential for disease modification rather than symptomatic relief
A preclinical program targeting tau protein pathology.
| Property |
Description |
| Type |
Monoclonal antibody |
| Target |
Tau protein aggregates |
| Indication |
Alzheimer's Disease |
| Mechanism |
Anti-tau antibody to block propagation |
| Phase |
Preclinical |
TrueBinding's antibody platform focuses on:
- Novel Epitopes: Targeting unique conformational epitopes on amyloid-beta
- Oligomer Specificity: High affinity for toxic oligomeric species
- Plaque Binding: Ability to bind and facilitate clearance of aggregated plaques
- Pathology Blocking: Antibodies designed to prevent spread of tau pathology
- Neurofibrillary Tangle Targeting: Potential to clear existing tangles
- Trial Design: Dose-escalation study in healthy volunteers and AD patients
- Primary Endpoints: Safety and tolerability
- Secondary Endpoints: Biomarker changes, pharmacokinetics
¶ Competitive Landscape
TrueBinding competes with other Alzheimer's antibody developers:
¶ Research and Development Focus
TrueBinding's R&D priorities include:
- Antibody Discovery: Novel antibody generation against neurodegenerative targets
- Epitope Mapping: Understanding precise binding sites on target proteins
- Blood-Brain Barrier Delivery: Improving CNS penetration
- Biomarker Development: Patient selection and treatment response markers
- Academic Collaborations: Research partnerships with universities
- Contract Manufacturing: CMC partnerships for clinical supply
- Clinical Sites: Trial site partnerships
¶ Challenges in Alzheimer's Antibody Development
- Amyloid-Related Imaging Abnormalities (ARIA): Risk of brain edema and hemorrhage
- Blood-Brain Barrier Penetration: CNS delivery challenges
- Patient Selection: Identifying patients most likely to respond
- Clinical Trial Design: Appropriate endpoints for disease modification
TrueBinding's long-term vision includes:
- Advancing TB-001 through clinical development
- Expanding TB-002 into clinical trials
- Exploring combination therapies
- Investigating other neurodegenerative indications